CARDIAC RESYNCHRONIZATION AND DEFIBRILLATOR THERAPY (CRT-D) OR CRT ALONE (CRT-P) IN PATIENTS WITH DILATED CARDIOMYOPATHY AND HEART FAILURE WITHOUT LATE GADOLINIUM ENHANCEMENT (LGE) CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) HIGH-RISK MARKERS - CRT-REALITY STUDY - STUDY DESIGN AND RATIONALE

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27283933%3A_____%2F21%3A00009786" target="_blank" >RIV/27283933:_____/21:00009786 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/22:10435465 RIV/00159816:_____/22:00077899 RIV/00023001:_____/22:00083421 RIV/00098892:_____/22:10157606 and 5 more

Result on the web

<a href="https://biomed.papers.upol.cz/pdfs/bio/2022/02/08.pdf" target="_blank" >https://biomed.papers.upol.cz/pdfs/bio/2022/02/08.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2021.015" target="_blank" >10.5507/bp.2021.015</a>

Result language

angličtina

Original language name

CARDIAC RESYNCHRONIZATION AND DEFIBRILLATOR THERAPY (CRT-D) OR CRT ALONE (CRT-P) IN PATIENTS WITH DILATED CARDIOMYOPATHY AND HEART FAILURE WITHOUT LATE GADOLINIUM ENHANCEMENT (LGE) CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) HIGH-RISK MARKERS - CRT-REALITY STUDY - STUDY DESIGN AND RATIONALE

Original language description

Background: Primary preventive implantation of implantable defibrillator (ICD) is according to current guidelines indicated in patients with heart failure NYHA (New York Heart Association) class II/III and LVEF b35%. Thanks to advances in heart failure pharmacotherapy, a decrease in mortality could render a benefit of ICD insufficient to justify its implantation in some patients. Methods: Study design: multicenter, prospective, randomized, controlled trial evaluating the benefit of implantation of Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in non-ischemic patients with reduced left ventricle ejection fraction (LVEF) and optimal pharmacotherapy without significant mid-wall myocardial fibrosis detected by cardiac magnetic resonance (CMR). The primary end-point: Re-hospitalization for heart failure, ventricular tachycardia, major adverse cardiac events (MACE). The secondary end-points: Sudden cardiac death, cardiovascular death, resuscitated cardiac arrest or sustained ventricular tachycardia, device-related complications, and change in quality of life. Course of the study: After a pharmacotherapy is optimized and significant mid-wall myocardial fibrosis excluded, patients will be randomized 1:1 to CRT-P or CRT-D implantation. Discussion: If our hypothesis is confirmed, this could provide evidence for the management of these patients with a significant impact on common daily praxis and health care expenditures.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Volume of the periodical

—

Issue of the periodical within the volume

2

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

7

Pages from-to

173-179

UT code for WoS article

000731340300001

EID of the result in the Scopus database

—